{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T18:47:31Z","timestamp":1777056451449,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T00:00:00Z","timestamp":1698969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ophthalmologyscience.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Science"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.xops.2023.100426","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T15:12:06Z","timestamp":1699369926000},"page":"100426","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Double-Masked, Vehicle-Controlled, Randomized, Phase II Study of the Ocular Hypotensive Activity and Safety of VVN539 Ophthalmic Solution"],"prefix":"10.1016","volume":"4","author":[{"given":"David","family":"Wirta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary D.","family":"Novack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Christie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Hartman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Tafoya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Navin","family":"Tekwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wirta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xops.2023.100426_bib1","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMra0804630","article-title":"Primary open-angle glaucoma","volume":"360","author":"Kwon","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.xops.2023.100426_bib2","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/IJG.0000000000002083","article-title":"Primary open angle glaucoma prevalence in Europe: A systematic review and meta-analysis","volume":"31","author":"Gallo Afflitto","year":"2022","journal-title":"J\u00a0Glaucoma"},{"key":"10.1016\/j.xops.2023.100426_bib3","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.ophtha.2021.04.009","article-title":"The global extent of undetected glaucoma in adults: A systematic review and meta-analysis","volume":"128","author":"Soh","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100426_bib4","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100426_bib5","doi-asserted-by":"crossref","first-page":"P151","DOI":"10.1016\/j.ophtha.2020.10.023","article-title":"Primary open-angle glaucoma preferred practice pattern\u00ae","volume":"128","author":"Gedde","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100426_bib6","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/ceo.13989","article-title":"Medical therapy for glaucoma: a review","volume":"50","author":"Casson","year":"2022","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib7","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1007\/s12325-023-02534-w","article-title":"Crossover randomized study of pharmacologic effects of ripasudil-brimonidine fixed-dose combination versus ripasudil or brimonidine","volume":"40","author":"Tanihara","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.xops.2023.100426_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ogla.2022.08.015","article-title":"Phase I\/II, double-masked, randomized, vehicle-controlled study of H-1337 ophthalmic solution for glaucoma and ocular hypertension","volume":"6","author":"Hartman","year":"2023","journal-title":"Ophthalmol Glaucoma"},{"key":"10.1016\/j.xops.2023.100426_bib9","first-page":"150","article-title":"Discovery and preclinical development of VVN539, a novel ROCK and NO dual MOA agent for the treatment of glaucoma in normotensive rabbits model with minimal hyperemia","volume":"63","author":"Li","year":"2022","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.xops.2023.100426_bib10","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.ajo.2016.05.012","article-title":"Comparison of Latanoprostene Bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study","volume":"168","author":"Medeiros","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib11","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1089\/jop.2016.0188","article-title":"The role of nitric oxide in the intraocular pressure lowering efficacy of Latanoprostene Bunod: review of nonclinical studies","volume":"34","author":"Cavet","year":"2018","journal-title":"J\u00a0Ocul Pharmacol Ther"},{"key":"10.1016\/j.xops.2023.100426_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/BF00877117","article-title":"Mechanisms of action of nitrates","volume":"8","author":"Torfg\u00e5rd","year":"1994","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.xops.2023.100426_bib13","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0021-9258(17)42402-1","article-title":"Purification and reconstitution of the high-conductance, calcium-activated potassium channel from tracheal smooth muscle","volume":"269","author":"Garcia-Calvo","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.xops.2023.100426_bib14","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ajo.2011.04.012","article-title":"Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension","volume":"152","author":"Williams","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib15","first-page":"112","article-title":"Primary glaucomas. Gonioscopy, ophthalmoscopy and perimetry","volume":"64","author":"Shaffer","year":"1960","journal-title":"Trans Am Acad Ophthalmol Otolaryngol"},{"key":"10.1016\/j.xops.2023.100426_bib16","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1001\/archophthalmol.2009.96","article-title":"An objective evaluation of eyedrop instillation in patients with glaucoma","volume":"127","author":"Stone","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib17","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/archopht.124.9.1230","article-title":"Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial","volume":"124","author":"Sherwood","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ajo.2022.11.017","article-title":"Ripasudil-Brimonidine fixed-dose combination vs ripasudil or brimonidine: two Phase 3 randomized clinical trials","volume":"248","author":"Tanihara","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two Phase 3 clinical trials comparing the safety and efficacy of Netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment Trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib20","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1001\/jamaophthalmol.2015.0525","article-title":"Additive intraocular pressure-lowering effects of the Rho kinase inhibitor ripasudil (K-115) combined with timolol or latanoprost: A report of 2 randomized clinical trials","volume":"133","author":"Tanihara","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.xops.2023.100426_bib21","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.ophtha.2023.06.012","article-title":"Placebo effect and its determinants in ocular hypotensive therapy: meta-analysis and multiple meta-regression analysis","volume":"130","author":"Choe","year":"2023","journal-title":"Ophthalmology"},{"key":"10.1016\/j.xops.2023.100426_bib22","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/s12325-020-01227-y","article-title":"Effects of Netarsudil and latanoprost alone and in fixed combination on corneal endothelium and corneal thickness: post-hoc analysis of MERCURY-2","volume":"37","author":"Wisely","year":"2020","journal-title":"Adv Ther"}],"container-title":["Ophthalmology Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914523001586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666914523001586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T06:24:16Z","timestamp":1763015056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666914523001586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2666914523001586"],"URL":"https:\/\/doi.org\/10.1016\/j.xops.2023.100426","relation":{},"ISSN":["2666-9145"],"issn-type":[{"value":"2666-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Double-Masked, Vehicle-Controlled, Randomized, Phase II Study of the Ocular Hypotensive Activity and Safety of VVN539 Ophthalmic Solution","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xops.2023.100426","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}],"article-number":"100426"}}